Animal Venom Peptides as a New Frontier for Diabetes Drug Discovery | Research

The takeaway

Beyond exendin-4 (the basis for exenatide), venom-derived peptides from bees, cone snails, sea anemones, scorpions, snakes, and spiders show therapeutic potential for managing blood sugar in diabetes.

6+ animal groups with anti-diabetic peptides
Bees, cone snails, sea anemones, scorpions, snakes, and spiders — building on exendin-4's success

What the researchers found

Venom-derived peptides from diverse species (bees, cone snails, sea anemones, scorpions, snakes, spiders) show potential for glycemic control, building on the proven success of exendin-4/exenatide.

Why it matters

Diabetes affects nearly 500 million people worldwide. Natural venom peptides offer optimized molecular scaffolds that evolution has refined for billions of years, potentially yielding more effective drugs than synthetic design alone.

The numbers in context

7+ species: Gila monster, bee, cone snail, sea anemone, scorpion, snake, spider; exenatide proof-of-concept

How the study worked

Review of published literature on venom-derived peptide compounds with anti-diabetic potential, including drug development pathways from discovery through clinical trials.

Who was studied

Review of venom-derived peptide research for diabetes across multiple species

What this study cannot tell us

Review article without new experimental data. Many venom-derived compounds are in early research stages. Translation from animal venom to approved drug is lengthy and expensive.

How to read the evidence

Review covering a range of evidence from early discovery to FDA-approved drugs. Evidence strength varies by compound and stage of development.

When this study was published

Published in 2021, capturing the expanding landscape of venom-derived diabetes therapeutics.

The bigger picture

Natural product drug discovery from animal venoms represents a rich and underexplored pharmaceutical resource. The success of exenatide demonstrates that venom peptides can become blockbuster drugs, and expanding this approach to more species and targets could yield the next generation of diabetes treatments.

Questions still open

Which venom-derived peptides are closest to clinical development for diabetes?
Could venom peptides target diabetic complications beyond blood sugar control?
How can high-throughput venom screening accelerate drug discovery?

Common questions

How can animal venom help treat diabetes?

Animal venoms contain peptides that evolution has optimized to interact with biological systems. Some of these peptides affect blood sugar regulation. The most famous example is exendin-4 from Gila monster saliva, which became the diabetes drug exenatide. Researchers are now finding similar compounds in venom from bees, snakes, and other animals.

Why are venom peptides better than synthetic drugs?

Venom peptides have been refined by millions of years of evolution to be highly bioactive, specific, and stable. These properties make them superior starting points for drug development compared to many synthetic compounds designed from scratch in the laboratory.

Read the original research

Therapeutic Potential of Peptides Derived from Animal Venoms: Current Views and Emerging Drugs for Diabetes.

Clinical medicine insights. Endocrinology and diabetes, 14, 11795514211006071

View on PubMed ↗Publisher’s paper ↗

Citation

Coulter-Parkhill, Aimee; McClean, Stephen; Gault, Victor A; Irwin, Nigel. (2021). Therapeutic Potential of Peptides Derived from Animal Venoms: Current Views and Emerging Drugs for Diabetes.. Clinical medicine insights. Endocrinology and diabetes, 14, 11795514211006071. https://doi.org/10.1177/11795514211006071